LAG3 and hepatocellular carcinoma: For LAG-3, clinical experience in HCC is nascent (e.g., nivolumab + relatlimab trials), while preclinical work combining anti-LAG-3 + anti-PD-1 + STING agonism shows synergistic suppression and enables LAG-3–targeted PET as a pharmacodynamic read-out [49].